Abbott Prevails In $219M Whistleblower FCA Trial

By Jess Krochtengel · April 7, 2016, 5:58 PM EDT

A Texas federal jury on Thursday cleared Abbott Laboratories of accusations it improperly marketed bile duct stents for off-label uses, in a whistleblower False Claims Act case that had sought $219...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

USA v. Abbott Laboratories et al

Case Number

3:06-cv-01769

Court

Texas Northern

Nature of Suit

Other Statutes: Other Statutory Actions

Date Filed

September 26, 2006